HIV Infections
Conditions
Keywords
HIV Infections, Intermittent Triple Therapy
Brief summary
The strategy of intermittent triple therapy for people living with HIV was validated in France following the randomized clinical trial QUATUOR. There is little data in real life, as shown in the meta-analysis of Parienti JJ et al. Currently this strategy is proposed by some teams in France, but is not recommended internationally. The research hypothesis is that intermittent treatment is an effective and safe option in a therapeutic lightening strategy in people living with HIV People living with HIV adults followed in Strasbourg who have benefited from intermittent treatment The expected results will consist of an improvement in knowledge on the efficacy and tolerance of this therapeutic strategy.
Interventions
None listed
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult subject (≥ 18 years old) * Living with HIV monitored at the Trait d'Union/Infectious Diseases department in Strasbourg * Having benefited from intermittent triple therapy between 01/01/2017 and 31/01/2024
Exclusion criteria
* Subject (and/or their legal representative if applicable) having expressed their opposition to the reuse of their data for scientific research purposes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of HIV viral load | 48 weeks after reduction of the HIV viral load |
Countries
France
Contacts
Primary ContactAxel URSENBACH, MD
Outcome results
None listed